β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Preserved Ejection Fraction

β-blockers after myocardial infarction in patients with preserved ejection fraction (LVEF ≥50%) do not significantly improve key outcomes like mortality or recurrent events. This addresses a common query: How effective are β-blockers in post-heart attack care for those with normal heart function? A recent meta-analysis in JAMA Cardiology pooled data from four major trials with nearly 20,000 patients. Published January 7, 2026, it challenges traditional use of these drugs in this group. These results could reshape guidelines in modern cardiology.

The analysis reveals key details on β-blockers in myocardial infarction therapy for patients with preserved left ventricular ejection fraction (LVEF ≥50%). Traditional beta-adrenergic blockers, often used to manage heart rate and rhythm, show limited benefits here. Below are the main findings:

• No Drop in All-Cause Mortality: In 19,826 patients followed for 3.5 to 5 years, β-blocker use had a relative risk (RR) of 1.02 (95% CI, 0.88-1.19). This indicates no real difference from controls.
• No Clear Benefits for Heart Events: Cardiovascular death showed an RR of 1.25 (95% CI, 0.94-1.68). Recurrent myocardial infarction had an RR of 0.89 (95% CI, 0.78-1.03). Heart failure hospitalization was neutral at RR 0.87 (95% CI, 0.64-1.18), and unplanned revascularization showed RR 1.04 (95% CI, 0.87-1.23). None reached statistical significance.
• Differences from Mildly Reduced LVEF: Prior studies suggest gains for LVEF 40%-49%. But for preserved cases, often treated with percutaneous coronary intervention (PCI), routine β-blockers add little value.

These points stress personalized secondary prevention after acute coronary syndromes. Factors like ventricular remodeling and other meds, such as statins, play key roles.

Background Context

Why this meta-analysis now? β-blockers have been a cornerstone of post-myocardial infarction treatment, especially for reduced ejection fraction (≤40%) to prevent arrhythmias. Evidence for preserved LVEF (≥50%) has been unclear. Trials like REBOOT-CNIC found neutral effects, while BETAMI-DANBLOCK suggested some gains.

Led by Linjie Li and Jingge Li, researchers followed PRISMA guidelines. They reviewed studies up to August 30, 2025, and picked four strong randomized trials: CAPITAL-RCT, REDUCE-AMI, REBOOT-CNIC, and BETAMI-DANBLOCK. These open-label trials targeted acute MI patients with LVEF >40% (or >50% in REDUCE-AMI), involving 19,826 people.

Key methods included:

• Data Collection: Two reviewers extracted details like mean age (61-65 years), 80% male participants, and PCI rates over 92%.
• Analysis Method: They used the Mantel-Haenszel fixed-effect model in R version 4.5.1 for relative risks and 95% CIs, focusing on LVEF ≥50% subgroups from published data.
• Trial Features: Most patients got aspirin (95-98%), P2Y12 inhibitors (88-98%), and statins (90-98%), matching real-world care.

This approach builds trust through large, up-to-date trials. For full trial data and visuals, dive into the original meta-analysis.

Implications

How do these findings affect cardiology and health economics? In post-MI care, therapies must weigh benefits, costs, and quality of life. This study questions routine β-blockers for preserved ejection fraction, which could cut unnecessary prescriptions and side effects like fatigue or slow heart rate.

Economically, it may reduce spending on secondary prevention. β-blockers work well for reduced LVEF but seem redundant here, thanks to PCI and statins. Research could now target subgroups via biomarkers for better resource use. Clinically, guidelines might de-emphasize β-blockers in low-risk cases, emphasizing lifestyle changes or new drugs for value-based care.

For mildly reduced LVEF, benefits remain, supporting tailored plans. To explore β-blockers myocardial infarction strategies further, check the detailed analysis.

FAQ

How do β-blockers impact outcomes after myocardial infarction for patients with preserved ejection fraction?
They show no significant benefits in reducing mortality, recurrent infarction, or heart failure in this group (LVEF ≥50%), unlike in reduced function cases.

What changes might this bring to post-heart attack treatment guidelines?
Guidelines could limit β-blockers to LVEF <50%, reducing overtreatment and prioritizing proven options like PCI and statins.

What are the main limitations of this meta-analysis?
It used aggregate data, not individual records, which limits deep subgroup analysis. It also drew from just four trials, some not solely for preserved LVEF.